DNA-based influenza vaccines as immunoprophylactic agents toward universality

Future Microbiology

Volumn 11, Issue 1, 2016, Pages 153-164

  Zhang, Han ^a   El Zowalaty, Mohamed E ^b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Qatar University   (Qatar)

Author keywords

delivery; DNA vaccines; immunoprophylaxis; influenza; pandemics; universal; virus

Indexed keywords

DNA VACCINE; INFLUENZA DNA VACCINE; INFLUENZA VACCINE; UNCLASSIFIED DRUG;

ANTIGENIC VARIATION; BORDETELLA PERTUSSIS; CD8+ T LYMPHOCYTE; CROSS PROTECTION; HUMAN; IMMUNOGENICITY; INFLUENZA; INFLUENZA A VIRUS (H10N8); INFLUENZA A VIRUS (H1N1); INFLUENZA A VIRUS (H2N2); INFLUENZA A VIRUS (H3N2); INFLUENZA A VIRUS (H7N2); INFLUENZA A VIRUS (H7N3); INFLUENZA A VIRUS (H7N7); INFLUENZA A VIRUS (H7N9); INFLUENZA A VIRUS (H9N2); LACTOCOCCUS LACTIS; NONHUMAN; PRIORITY JOURNAL; REVIEW; SALMONELLA ENTERICA SEROVAR TYPHIMURIUM; VACCINE PRODUCTION; VIRUS MORPHOLOGY; ANIMAL; DISEASE MODEL; DISEASE TRANSMISSION; DRUG DEVELOPMENT; GENETICS; IMMUNOLOGY; INFLUENZA, HUMAN; PREVENTION AND CONTROL; TRENDS;

ANIMALS; DISEASE MODELS, ANIMAL; DISEASE TRANSMISSION, INFECTIOUS; DRUG DISCOVERY; HUMANS; INFLUENZA VACCINES; INFLUENZA, HUMAN; VACCINES, DNA;

EID: 84952642612     PISSN: 17460913     EISSN: 17460921     Source Type: Journal    
DOI: 10.2217/fmb.15.110     Document Type: Review

References (111)

1. El Zowalaty ME, Bustin SA, Husseiny MI, Ashour HM. Avian influenza: virology, diagnosis and surveillance. Future Microbiol. 8(9), 1209-1227 (2013).
2. World Health Organization. Influenza fact sheet (2014). http://www.who.int
3. Bouvier NM, Lowen AC. Animal models for influenza virus pathogenesis and transmission. Viruses 2(8), 1530-1563 (2010).
4. Horimoto T, Kawaoka Y. Influenza: lessons from past pandemics, warnings from current incidents. Nat. Rev. Microbiol. 3(8), 591-600 (2005).
5. Baltimore D. Expression of animal virus genomes. Bacteriological Reviews 35(3), 235 (1971).
6. Ducatez MF, Pelletier C, Meyer G. Influenza D Virus in Cattle. France, 2011-2014. Emerg. Infect. Dis. 21(2) 368-371 (2015).
7. Hause BM, Collin EA, Liu R et al. Characterization of a novel influenza virus in cattle and swine: proposal for a new genus in the Orthomyxoviridae family. MBio 5(2), e00031-00014 (2014).
8. Hause BM, Ducatez M, Collin EA et al. Isolation of a novel swine influenza virus from Oklahoma in 2011 which is distantly related to human influenza C viruses. PLoS Pathog. 9(2), e1003176 (2013).
9. Muramoto Y, Noda T, Kawakami E, Akkina R, Kawaoka Y. Identification of novel influenza A virus proteins translated from PA mRNA. J. Virol. 87(5), 2455-2462 (2013).
10. Vasin A, Temkina O, Egorov V, Klotchenko S, Plotnikova M, Kiselev O. Molecular mechanisms enhancing the proteome of influenza A viruses: an overview of recently discovered proteins. Virus Res. 185, 53-63 (2014).
11. Tong S, Li Y, Rivailler P et al. A distinct lineage of influenza A virus from bats. Proc. Natl Acad. Sci. USA 109(11), 4269-4274 (2012).
12. Wu Y, Wu Y, Tefsen B, Shi Y, Gao GF. Bat-derived influenza-like viruses H17N10 and H18N11. Trends Microbiol. 22(4), 183-191 (2014).
13. Tong S, Zhu X, Li Y et al. New world bats harbor diverse influenza A viruses. PLoS Pathog. 9(10), e1003657 (2013).
14. Medina RA, García-Sastre A. Influenza A viruses: new research developments. Nat. Rev. Microbiol. 9(8), 590-603 (2011).
15. Arzey GG, Kirkland PD, Arzey KE et al. Influenza virus A (H10N7) in chickens and poultry abattoir workers, Australia. Emerg. Infect. Dis. 18(5), 814-816 (2012).
16. Chen H, Yuan H, Gao R et al. Clinical and epidemiological characteristics of a fatal case of avian influenza A H10N8 virus infection: A descriptive study. Lancet 383(9918), 714-721 (2014).
17. Koopmans M, Wilbrink B, Conyn M et al. Transmission of H7N7 avian influenza A virus to human beings during a large outbreak in commercial poultry farms in The Netherlands. Lancet 363(9409), 587-593 (2004).
18. Lopez-Martinez I, Balish A, Barrera-Badillo G et al. Highly pathogenic avian influenza A (H7N3) virus in poultry workers, Mexico, 2012. Emerg. Infect. Dis. 19(9), 1531 (2013).
19. Ostrowsky B, Huang A, Terry W et al. Low pathogenic avian influenza A (H7N2) virus infection in immunocompromised adult, New York, USA, 2003. Emerg. Infect. Dis. 18(7), 1128 (2012).
20. Nabel GJ, Fauci AS. Induction of unnatural immunity: prospects for a broadly protective universal influenza vaccine. Nat. Med. 16(12), 1389-1391 (2010).
21. Pica N, Palese P. Toward a universal influenza virus vaccine: prospects and challenges. Ann. Rev. Med. 64, 189-202 (2013).
22. To KK, Chan JF, Chen H, Li L, Yuen K-Y. The emergence of influenza A H7N9 in human beings 16 years after influenza A H5N1: A tale of two cities. Lancet Infect. Dis. 13(9), 809-821 (2013).
23. Uyeki TM, Cox NJ. Global concerns regarding novel influenza A (H7N9) virus infections. N. Engl. J. Med. 368(20), 1862-1864 (2013).
24. Liu J, Xiao H, Wu Y, et al. H7N9: A low pathogenic avian influenza A virus infecting humans. Curr. Opin. Virol. 5, 91-97 (2014).
25. Shi Y, Wu Y, Zhang W, Qi J, Gao GF. Enabling the 'host jump': structural determinants of receptor-binding specificity in influenza A viruses. Nat. Rev. Microbiol. 12(12), 822-831 (2014).
26. Wang L, Zhang H, Compans RW, Wang B-Z. Universal influenza vaccines-A short review. J. Immunol. Clin. Res.1, 1003-1009 (2013).
27. Laurie KL, Guarnaccia TA, Carolan LA et al. The time-interval between infections and viral hierarchies are determinants of viral interference following influenza virus infection in a ferret model. J. Infect. Dis. 212(11), 1701-1710 (2015).
28. United States Centers for Disease Control and Prevention. Seasonal influenza: selecting the viruses in the seasonal influenza (Flu) vaccine. CDC, GA, USA (2014). http://www.cdc.gov
29. United States Centers for Disease Control and Prevention. Seasonal influenza: what you should know for the 2014-2015 influenza. CDC, GA, USA (2014). http://www.cdc.gov
30. Ulmer JB. Influenza DNA vaccines. Vaccine 20, S74-S76 (2002).
31. Stachyra A, Góra-Sochacka A, Sirko A. DNA vaccines against influenza. Acta Biochim. Pol. 61(3), 515-522 (2014).
32. Donnelly JJ, Wahren B, Liu MA. DNA vaccines: progress and challenges. J. Immunol. 175(2), 633-639 (2005).
33. Lillie PJ, Berthoud TK, Powell TJ et al. Preliminary assessment of the efficacy of a T-cell-based influenza vaccine, MVA-NP+ M1, in humans. Clin. Infect. Dis. cis327 (2012).
34. Zhang H, Wang L, Compans RW, Wang B-Z. Universal influenza vaccines, a dream to be realized soon. Viruses 6(5), 1974-1991 (2014).
35. Okuda K, Ihata A, Watabe S et al. Protective immunity against influenza A virus induced by immunization with DNA plasmid containing influenza M gene. Vaccine 19(27), 3681-3691 (2001).
36. Iurescia S, Fioretti D, Rinaldi M. Strategies for improving DNA vaccine performance. In: DNA Vaccines. Springer, ISBN 978-1-4939-0410-5, 21-31 (2014).
37. Kutzler MA, Weiner DB. DNA vaccines: ready for prime time? Nat. Rev. Genet. 9(10), 776-788 (2008).
38. Liu M. DNA vaccines: A review. J. Int. Med. 253(4), 402-410 (2003).
39. Sasaki S, Takeshita F, Xin K-Q, Ishii N, Okuda K. Adjuvant formulations and delivery systems for DNA vaccines. Methods 31(3), 243-254 (2003).
40. Khan KH. DNA vaccines: roles against diseases. Germs 3(1), 26 (2013).
41. Zhou F, Wang G, Buchy P et al. A triclade DNA vaccine designed on the basis of a comprehensive serologic study elicits neutralizing antibody responses against all clades and subclades of highly pathogenic avian influenza H5N1 viruses. J. Virol. 86(12), 6970-6978 (2012).
42. Laddy DJ, Weiner DB. From plasmids to protection: A review of DNA vaccines against infectious diseases. Int. Rev. Immunol. 25(3-4), 99-123 (2006).
43. Liu MA. DNA vaccines: an historical perspective and view to the future. Immunol. Rev. 239(1), 62-84 (2011).
44. Yager EJ, Dean HJ, Fuller DH. Prospects for developing an effective particle-mediated DNA vaccine against influenza. Expert Rev. Vaccines 8(9), 1205-1220 (2009).
45. Du L, Zhou Y, Jiang S. Research and development of universal influenza vaccines. Microbes Infect. 12(4), 280-286 (2010).
46. Ulmer JB, Donnelly JJ, Parker SE et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 259(5102), 1745-1749 (1993).
47. Lei H, Xu Y, Chen J, Wei X, Lam DM. Immunoprotection against influenza H5N1 virus by oral administration of enteric-coated recombinant Lactococcus lactis mini-capsules. Virology 407(2), 319-324 (2010).
48. Luo J, Zheng D, Zhang W et al. Induction of cross-protection against influenza A virus by DNA prime-intranasal protein boost strategy based on nucleoprotein. Virol. J. 9, 286 (2012).
49. Grodeland G, Mjaaland S, Roux KH, Fredriksen AB, Bogen B. DNA vaccine that targets hemagglutinin to MHC class II molecules rapidly induces antibody-mediated protection against influenza. J. Immunol. 191(6), 3221-3231 (2013).
50. Alexander J, Bilsel P, Del Guercio MF et al. Universal influenza DNA vaccine encoding conserved CD4+ T cell epitopes protects against lethal viral challenge in HLA-DR transgenic mice. Vaccine 28(3), 664-672 (2010).
51. Pandemic Influenza Synthetic DNA Vaccine. http://www.Inovio.Level3.Pint.com
52. Hoelscher MA, Garg S, Bangari DS et al. Development of adenoviral-vector-based pandemic influenza vaccine against antigenically distinct human H5N1 strains in mice. Lancet 367(9509), 475-481 (2006).
53. Mooney AJ, Li Z, Gabbard JD, He B, Tompkins SM. Recombinant parainfluenza virus 5 vaccine encoding the influenza virus hemagglutinin protects against H5N1 highly pathogenic avian influenza virus infection following intranasal or intramuscular vaccination of BALB/c mice. J. Virol. 87(1), 363-371 (2013).
54. Li Z, Gabbard JD, Mooney A, Chen Z, Tompkins SM, He B. Efficacy of parainfluenza virus 5 mutants expressing hemagglutinin from H5N1 influenza A virus in mice. J. Virol. 87(17), 9604-9609 (2013).
55. Kreijtz J, Suezer Y, De Mutsert G et al. Preclinical evaluation of a modified vaccinia virus Ankara (MVA)-based vaccine against influenza A/H5N1 viruses. Vaccine 27(45), 6296-6299 (2009).
56. Van Kampen KR, Shi Z, Gao P et al. Safety and immunogenicity of adenovirus-vectored nasal and epicutaneous influenza vaccines in humans. Vaccine 23(8), 1029-1036 (2005).
57. Yang S-G, Wo J-E, Li M-W et al. Construction and cellular immune response induction of HA-based alphavirus replicon vaccines against human-avian influenza (H5N1). Vaccine 27(52), 7451-7458 (2009).
58. Nayak S, Herzog RW. Progress and prospects: immune responses to viral vectors. Gene Ther. 17(3), 295-304 (2010).
59. Sedova ES, Shcherbinin DN, Migunov AI et al. Recombinant influenza vaccines. Acta Naturae 4(4), 17-27 (2012).
60. Colloca S, Barnes E, Folgori A et al. Vaccine vectors derived from a large collection of simian adenoviruses induce potent cellular immunity across multiple species. Sci. Translat. Med. 4(115), 115ra112 (2012).
61. Tatsis N, Fitzgerald JC, Reyes-Sandoval A et al. Adenoviral vectors persist in vivo and maintain activated CD8+ T cells: implications for their use as vaccines. Blood 110(6), 1916-1923 (2007).
62. Xiang ZQ, Yang Y, Wilson JM, Ertl HC. A replication-defective human adenovirus recombinant serves as a highly efficacious vaccine carrier. Virology 219(1), 220-227 (1996).
63. Gurwith M, Lock M, Taylor EM et al. Safety and immunogenicity of an oral, replicating adenovirus serotype 4 vector vaccine for H5N1 influenza: A randomised, double-blind, placebo-controlled, Phase 1 study. Lancet Infect. Dis. 13(3), 238-250 (2013).
64. Baden LR, Walsh SR, Seaman MS et al. First-in-human evaluation of the safety and immunogenicity of a recombinant adenovirus serotype 26 HIV-1 Env vaccine (IPCAVD 001). J. Infect. Dis. 207(2), 240-247 (2013).
65. Alexander J, Ward S, Mendy J et al. Pre-clinical evaluation of a replicationcompetent recombinant adenovirus serotype 4 vaccine expressing influenza H5 hemagglutinin. PLoS ONE 7(2), e31177 (2012).
66. Tatsis N, Ertl HC. Adenoviruses as vaccine vectors. Mol. Ther. 10(4), 616-629 (2004).
67. Abbink P, Lemckert AA, Ewald BA et al. Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D. J. Virol. 81(9), 4654-4663 (2007).
68. Sipo I, Knauf M, Fechner H et al. Vaccine protection against lethal homologous and heterologous challenge using recombinant AAV vectors expressing codon-optimized genes from pandemic swine origin influenza virus (SOIV). Vaccine 29(8), 1690-1699 (2011).
69. Vemula SV, Ahi YS, Swaim AM et al. Broadly protective adenovirus-based multivalent vaccines against highly pathogenic avian influenza viruses for pandemic preparedness. PLoS ONE 8(4), e62496 (2013).
70. Hoelscher MA, Singh N, Garg S et al. A broadly protective vaccine against globally dispersed clade 1 and clade 2 H5N1 influenza viruses. J. Infect. Dis. 197(8), 1185-1188 (2008).
71. Tutykhina IL, Logunov DY, Shcherbinin DN et al. Development of adenoviral vector-based mucosal vaccine against influenza. J. Mol. Med. (Berl.) 89(4), 331-341 (2011).
72. Kammoun H, Roux X, Raze D et al. Immunogenicity of live attenuated B. pertussis BPZE1 producing the universal influenza vaccine candidate M2e. PLoS ONE 8(3), e59198 (2013).
73. Reese KA, Lupfer C, Johnson RC et al. A novel lactococcal vaccine expressing a peptide from the M2 antigen of H5N2 highly pathogenic avian influenza A virus prolongs survival of vaccinated chickens. Vet. Med. Int. 2013, 316926 (2013).
74. Kong W, Brovold M, Koeneman BA, Clark-Curtiss J, Curtiss R 3rd. Turning self-destructing Salmonella into a universal DNA vaccine delivery platform. Proc. Natl Acad. Sci. USA 109(47), 19414-19419 (2012).
75. Langer B, Renner M, Scherer J, Schüle S, Cichutek K. Safety assessment of biolistic DNA vaccination. In: Biolistic DNA Delivery. Springer, USA, 371-388 (2013).
76. US FDA. Guidance for industry: considerations for plasmid DNA vaccines for infectious disease indications (2007). http://www.fda.gov
77. Faurez F, Dory D, Le Moigne V, Gravier R, Jestin A. Biosafety of DNA vaccines: New generation of DNA vectors and current knowledge on the fate of plasmids after injection. Vaccine 28(23), 3888-3895 (2010).
78. Ferraro B, Morrow MP, Hutnick NA, Shin TH, Lucke CE, Weiner DB. Clinical applications of DNA vaccines: current progress. Clin. Infect. Dis. 53(3), 296-302 (2011).
79. WHO. Guidelines for assuring the quality and nonclinical safety evaluation of DNA vaccines; WHO Technical Report Series No 941, 2007 Annex 1 (2007). http://www.who.int
80. European Medicines Agency, London, UK. Guideline on safety and efficacy follow-up-risk management of advanced therapy medicinal products (EMEA/149995/2009) (2009). http://www.ema.europa.eu
81. Laddy DJ, Yan J, Kutzler M et al. Heterosubtypic protection against pathogenic human and avian influenza viruses via in vivo electroporation of synthetic consensus DNA antigens. PLoS ONE 3(6), e2517 (2008).
82. Drape RJ, Macklin MD, Barr LJ, Jones S, Haynes JR, Dean HJ. Epidermal DNA vaccine for influenza is immunogenic in humans. Vaccine 24(21), 4475-4481 (2006).
83. Watabe S, Xin K-Q, Ihata A et al. Protection against influenza virus challenge by topical application of influenza DNA vaccine. Vaccine 19(31), 4434-4444 (2001).
84. Shen X, Söderholm J, Lin F et al. Influenza A vaccines using linear expression cassettes delivered via electroporation afford full protection against challenge in a mouse model. Vaccine 30(48), 6946-6954 (2012).
85. Ledgerwood J, Hu Z, Gordon I et al. Influenza virus H5 DNA vaccination is immunogenic by intramuscular and intradermal routes in humans. Clin. Vaccine Immunol. 19(11), 1792-1797 (2012).
86. Ledgerwood JE, Wei C-J, Hu Z et al. DNA priming and influenza vaccine immunogenicity: two Phase 1 open label randomised clinical trials. Lancet Infect. Dis. 11(12), 916-924 (2011).
87. Smith LR, Wloch MK, Ye M et al. Phase 1 clinical trials of the safety and immunogenicity of adjuvanted plasmid DNA vaccines encoding influenza A virus H5 hemagglutinin. Vaccine 28(13), 2565-2572 (2010).
88. Chang H, Huang C, Wu J et al. A single dose of DNA vaccine based on conserved H5N1 subtype proteins provides protection against lethal H5N1 challenge in mice pre-exposed to H1N1 influenza virus. Virol. J. 7(197), 422X-427X (2010).
89. Tan L, Lu H, Zhang D et al. Protection against H1N1 influenza challenge by a DNA vaccine expressing H3/H1 subtype hemagglutinin combined with MHC class II-restricted epitopes. Virol. J. 7(1), 363 (2010).
90. Chen M-W, Cheng T-JR, Huang Y et al. A consensus-hemagglutinin-based DNA vaccine that protects mice against divergent H5N1 influenza viruses. Proc. Natl Acad. Sci. USA 105(36), 13538-13543 (2008).
91. Jones S, Evans K, McElwaine-Johnn H et al. DNA vaccination protects against an influenza challenge in a double-blind randomised placebo-controlled Phase 1b clinical trial. Vaccine 27(18), 2506-2512 (2009).
92. Jing Liu JW, Wang B, Zeng S et al. Oral vaccination with a liposome-encapsulated influenza DNA vaccine protects mice against respiratory challenge infection. J. Med. Virol. 86(5), 886-894 (2013).
93. Torrieri-Dramard L, Lambrecht B, Ferreira HL, Van Den Berg T, Klatzmann D, Bellier B. Intranasal DNA vaccination induces potent mucosal and systemic immune responses and cross-protective immunity against influenza viruses. Mol. Ther. 19(3), 602-611 (2011).
94. Sardesai NY, Weiner DB. Electroporation delivery of DNA vaccines: prospects for success. Curr. Opin. Immunol. 23(3), 421-429 (2011).
95. Prausnitz MR, Mikszta JA, Cormier M, Andrianov AK. Microneedle-based vaccines. Curr. Topics Microbiol. Immunol. 333, 369-393 (2009).
96. Rajapaksa AE, Ho JJ, Qi A et al. Effective pulmonary delivery of an aerosolized plasmid DNA vaccine via surface acoustic wave nebulization. Respir. Res. 15(1), 60 (2014).
97. Gargett T, Grubor-Bauk B, Miller D et al. Increase in DNA vaccine efficacy by virosome delivery and co-expression of a cytolytic protein. Clin. Translat. Immunol. 3(6), e18 (2014).
98. Kheiri MT, Jamali A, Shenagari M et al. Influenza virosome/DNA vaccine complex as a new formulation to induce intra-subtypic protection against influenza virus challenge. Antivir. Res. 95(3), 229-236 (2012).
99. Jazayeri SD, Ideris A, Zakaria Z, Shameli K, Moeini H, Omar AR. Cytotoxicity and immunological responses following oral vaccination of nanoencapsulated avian influenza virus H5 DNA vaccine with green synthesis silver nanoparticles. J. Control. Release 161(1), 116-123 (2012).
100. Fagone P, Shedlock DJ, Bao H et al. Molecular adjuvant HMGB1 enhances anti-influenza immunity during DNA vaccination. Gene Ther. 18(11), 1070-1077 (2011).
101. Mcelhaney JE, Coler RN, Baldwin SL. Immunologic correlates of protection and potential role for adjuvants to improve influenza vaccines in older adults. Expert Rev. Vaccines 12(7), 759-766 (2013).
102. Dai J, Pei D, Wang B et al. Molecular adjuvant Ag85A enhances protection against influenza A virus in mice following DNA vaccination. Viruses 4(12), 3606-3624 (2012).
103. Sullivan SM, Doukas J, Hartikka J, Smith L, Rolland A. Vaxfectin: A versatile adjuvant for plasmid DNA-and protein-based vaccines. Expert Opin. Drug Deliv. 7(12), 1433-1446 (2010).
104. Bardiya N, Bae J-H. Influenza vaccines: recent advances in production technologies. Appl. Microbiol. Biotechnol. 67(3), 299-305 (2005).
105. Justewicz DM, Morin MJ, Robinson HL, Webster RG. Antibody-forming cell response to virus challenge in mice immunized with DNA encoding the influenza virus hemagglutinin. J. Virol. 69(12), 7712-7717 (1995).
106. Robinson HL, Pertmer TM. DNA vaccines for viral infections: basic studies and applications. Adv. Virus Res. 55, 1-74 (2000).
107. Hulo C, De Castro E, Masson P et al. ViralZone: A knowledge resource to understand virus diversity. Nucleic Acids Res. 39(Suppl. 1), D576-D582 (2011).
108. Masson P, Hulo C, De Castro E et al. ViralZone: recent updates to the virus knowledge resource. Nucleic Acids Res. 41(D1), D579-D583 (2013).
109. Swiss Institute of Bioinformatics. ViralZone: Influenza virus A. http://viralzone.expasy.org
110. El Zowalaty ME, Abin M, Chander Y, Redig PT, Goyal SM. Isolation of H5 avian influenza viruses from waterfowl in the upper Midwest region of the United States. Avian Dis. 55(2), 259-262 (2011).
111. El Zowalaty ME, Abin M, Raju S et al. Isolation of Avian influenza virus from polymerase chain reaction-negative cloacal samples of waterfowl. J. Vet. Diagn. Invest. 23(1), 87-90 (2011).